p53, bcl-2, and Bax expression in renal cell carcinoma

Urology

Volumn 51, Issue 6, 1998, Pages 1057-1061

  Vasavada, Sandip P ^a   Novick, Andrew C ^a   Williams, Bryan R G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; ONCOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADENOMA, OXYPHILIC; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032101601     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00132-0     Document Type: Article

References (18)

1. Thrasher J.B., Paulson D.F. Prognostic factors in renal cancer. Urol Clin North Am. 20:1993;247-262.
2. Dinney C.N., Awad S.A., Gayeski S.B. Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology. 39:1992;122-125.
3. Lowe S.W., Ruley H.E., Jacks T., et al. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
4. Uchida T., Shitaro T., Egawa S., et al. Infrequent involvement of p53 mutation and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol. 150:1993;1298-1301.
5. Kuczyk M.A., Serth J., Bomeyer C., et al. Detection of p53 gene alterations in renal cell carcinoma by micropreparation techniques of tumor specimens. Int J Cancer. 64:1995;399-406.
6. Bot F.J., Godschalk J.C., Krishnadath K.K., et al. Prognostic factors in renal cell carcinoma immunohistochemical detection of p53 protein versus clinicopathologic parameters . Int J Cancer. 57:1994;634-637.
7. Miyashita T., Krajewski S., Krajewska M., et al. Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vivo and in vitro. Oncogene. 9:1994;1799-1805.
8. Oda H., Nakatsuru Y., Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinoma. Cancer Res. 55:1995;658-662.
9. Reiter R.E., Anglard P., Liu S., et al. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 53:1993;3092-3097.
10. Chiou S.K., Rao L., White E. Bcl-2 blocks p53 dependent apoptosis. Mol Cell Biol. 14:1994;2556-2560.
11. Oltvai Z.N., Milliman C.L., Korsemeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
12. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell. 80:1995;293-299.
13. Watson A.J., Merritt A.J., Jones L.S., et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer. 73:1996;889-895.
14. Lipponen P., Pietiliamen T., Kosma V.M., et al. Apoptosis suppressing protein Bcl-2 is expressed in well differentiated breast carcinoma with favorable prognosis. J Pathol. 177:1995;49-55.
15. Henrisksen R., Wilander E., Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumors. Br J Cancer. 72:1995;1432-1437.
16. Tomita Y., Bilim V., Kawasaki T., et al. Frequent expression of Bcl-2 in renal cell carcinoma carrying wild type p53. Int J Cancer. 66:1996;322-325.
17. Sinicrope F.A., Ruan S.B., Cleary K.R., et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:1995;237-241.
18. Chemeris G., Loktinov A., Rempel A., et al. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Archiv. 426:1995;563-569.